drugset / Trial / NCT06001749
Psilocybin in Cancer Pain Study
Phase 2
Recruiting
15 enrolled
Yvan Beaussant, MD, MSci
Cy Biopharma · collabPancreatic Cancer North America · collab
NaSingle-groupOpen-labelTreatment
Summary
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)
Timeline
- Start
- 2024-09-23
- Primary completion
- 2026-07-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | — | Oral |